SciMed Biotech Podcast with Hugh McTavish of SquareX Pharmaceutical Corporation

Turning personal challenges into
pharmaceutical breakthroughs with Hugh McTavish of SquareX Pharmaceutical Corporation

In this episode of the SciMed Biotech Podcast, we sit down with Hugh McTavish, a man whose personal and professional life exemplifies the power of resilience. As the founder and CEO of SquareX Pharmaceutical Corporation and IGF Oncology, Hugh shares his unique journey from facing personal health challenges to pioneering new treatments in both cancer therapy and viral outbreaks.

Hugh’s story begins with his own battle with cancer, which not only propelled him to improve upon the treatments he received but also led him to establish IGF Oncology. His innovative approach to cancer treatment seeks to enhance the effectiveness of chemotherapy by targeting specific cellular mechanisms. In parallel, his struggle with frequent cold sores inspired the creation of SquareX, introducing a novel treatment that prevents herpes virus outbreaks, a product he first tested on himself.

Beyond his scientific achievements, Hugh is also the Executive Director of COVID-Sanity.org, a platform he founded in response to the social and psychological impacts of the COVID-19 lockdowns. His stance against the measures reflects his broader commitment to addressing overlooked issues in public health and policy.

Join us as Hugh discusses the intersections of his work as a biochemist, immunologist, and patent attorney, and how these diverse fields inform his approach to drug development. He also shares insights into the challenges of navigating the pharmaceutical industry, from securing patents to fostering strategic partnerships.

This episode is not just a dive into the mind of an inventor and entrepreneur but also a testament to the potential of turning adversities into opportunities that can revolutionize healthcare.